Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if ...

We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, we are going to take a look ...

Weight-loss drugs like Ozempic and Wegovy have become household names in recent years. But here's why they may not work for ...

A broader market trend observed ever since the Fed announced its September cut rate has been the volatility in the ...

Experts are now concerned that patients with Ozempic prescriptions will try to microdose at home, which could cause an ...

However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...